GlassScriptPhysician profile
Elysse Tom
NPI 1659806594
$4,646.17
in general payments reported to CMS, 2019-2025
16 companies · $1,368 in 2025
The $1,368 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $65.10 · 2023: $1,029 · 2024: $1,784 · 2025: $1,368.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,179.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $923.34 | 2021-2025 | Rocklatan, Rhopressa, Argos |
| Genentech USA, INC. | $775.43 | 2023-2025 | Vabysmo, Susvimo |
| Sight Sciences, INC. | $592.83 | 2024-2025 | Omni Surgical System |
| Regeneron Healthcare Solutions, INC. | $545.37 | 2022-2025 | Eylea Hd, Eylea |
| Dompe US, INC. | $370.78 | 2024-2025 | Oxervate |
| Astellas Pharma Global Development | $251.82 | 2024-2025 | Izervay |
| Mallinckrodt Hospital Products INC. | $239.68 | 2024-2025 | Acthar |
| Astellas Pharma US INC | $203.45 | 2023 | Izervay |
| Regeneron Pharmaceuticals, INC. | $135.63 | 2023-2024 | Eylea, Eylea Hd |
| Janssen Biotech, INC. | $121.86 | 2024 | Rybrevant |
| Oyster Point Pharma, INC. | $120.82 | 2024 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $112.48 | 2024 | Syfovre |
| Biogen, INC. | $102.02 | 2022-2023 | |
| Bausch & Lomb Americas INC. | $98.37 | 2023-2025 | Xipere, Visudyne, Stellaris |
| Beaver-Visitec International, INC. | $52.29 | 2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elysse Tom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.